Printer Friendly

U.S. BIOSCIENCE ACQUIRES PLANT IN THE NETHERLANDS; OPENS EXTON, PA., LABORATORY

 WEST CONSHOHOCKEN, Pa., May 3 /PRNewswire/ -- U.S. Bioscience, Inc. (AMEX: UBS), announced today it has acquired a manufacturing facility in Nijmegen, The Netherlands, and opened a new analytical laboratory in Exton, Pa.
 The Nijmegen plant was purchased from a unit of Montedison by USB Pharma B.V., a wholly owned subsidiary of U.S. Bioscience. Intended to produce pharmaceuticals for the treatment of cancer and AIDS in the European Community and other international markets, it is expected to be operational in early 1994 following refurbishment. The Nijmegan facility will also support clinical trial operations by producing all clinical grade materials for the company's investigational program of injectable products. The new laboratory in Exton complements the company's research and development programs through product evaluation and stability testing activities.
 The company said these modest investments will provide substantial internal control of manufacturing and product development required for the foreseeable future.
 Based in West Conshohocken, U.S. Bioscience is a pharmaceutical company specializing in the development and commercialization of products to increase the survival and quality of life for patients with cancer and allied diseases. The company's portfolio includes a broad spectrum of compounds, including two products for which new drug applications have been filed and two others in the late stages of development. One compound, altretamine, is marketed under the name Hexalen in the United States for the treatment of ovarian cancer.
 /delval/
 -0- 5/3/93
 /CONTACT: Robert I. Kriebel, senior vice president, finance and administration, U.S. Bioscience, 215-832-4503/
 (UBS)


CO: U.S. Bioscience, Inc. ST: Pennsylvania IN: MTC SU:

MH-TW -- DC019 -- 3793 05/03/93 12:24 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 3, 1993
Words:270
Previous Article:U.S. INVESTORS BOUGHT RECORD $51.5 BILLION FOREIGN SECURITIES IN 1992; FOREIGN INVESTORS SOLD U.S. EQUITIES
Next Article:CMC SECURITIES CORP. CMO, SERIES 1993-B & C RATED 'AAA' BY FITCH -- FITCH FINANCIAL WIRE --
Topics:


Related Articles
U.S. BIOSCIENCE OBTAINS RIGHTS TO SELL OVARIAN CANCER DRUG IN EUROPE AND ISRAEL
DELAWARE VALLEY'S ENTREPRENEUR OF THE YEAR AWARD SELECTS PHILIP S. SCHEIN, M.D.
U.S. BIOSCIENCE NAMES AYER-PTASZEK VICE PRESIDENT - MARKETING
U.S. BIOSCIENCE ANNOUNCES FIRST QUARTER RESULTS
MedImmune, Inc. to Acquire U.S. Bioscience, Inc. -Acquisition Provides Immediate Products and Infrastructure in Oncology-.
3DP Appoints Wendy L. Nagy Senior Vice President and General Counsel.
Harvard Bioscience expands in Spain.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters